Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.

NCT00864318 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT00864318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00864318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2009
Completion date
October 5, 2020
Enrollment
101 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumors